Certara

On-Demand Webinar

Extending the Value of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Learn how model-informed strategies support ADC labeling, dose optimization, and market access through integrated evidence…

CertaraApril 10, 2026

Webinar

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

CertaraApril 10, 2026

Press Release

Certara to Report First Quarter 2026 Financial Results on May 11th, 2026

Radnor, Pa. — April 9, 2026 -- Certara, Inc. (Nasdaq: CERT), a global leader in…

Danielle PillsburyApril 9, 2026

Blog

PK Parameters Explained: From Cmax to Clearance (and Why It Matters for Development Decisions)

Learn how key PK parameters such as Cmax, AUC, clearance, half life, and volume of…

CertaraApril 9, 2026

Announcement

Certara Appoints Dr. Britta Wagenhuber as Head of Quantitative Systems Pharmacology (QSP) Consultancy

Dr. Britta Wagenhuber has joined the company as Head of Quantitative Systems Pharmacology (QSP) Consultancy.

CertaraApril 8, 2026

Conference

AMWA NorCal Pacific Coast Conference

Danielle PillsburyApril 8, 2026

Case Study

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

HUTCHMED was preparing a New Drug Application (NDA) submission for FRUZAQLA® (fruquintinib) a drug developed…

CertaraApril 7, 2026

Webinar

Earning Regulatory Trust: Practical Strategies to Increase Model Acceptance in MIDD

CertaraApril 6, 2026

Blog

CDISC SEND Updates Nonclinical Drug Developers Need to Know

In this blog, Peggy Zorn explores updates to the Standard for Exchange of Nonclinical Data…

CertaraApril 6, 2026

Webinar

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Danielle PillsburyApril 2, 2026

Extending the Value of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

Certara to Report First Quarter 2026 Financial Results on May 11th, 2026

PK Parameters Explained: From Cmax to Clearance (and Why It Matters for Development Decisions)

Certara Appoints Dr. Britta Wagenhuber as Head of Quantitative Systems Pharmacology (QSP) Consultancy

AMWA NorCal Pacific Coast Conference

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

Earning Regulatory Trust: Practical Strategies to Increase Model Acceptance in MIDD

CDISC SEND Updates Nonclinical Drug Developers Need to Know

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Newsletter sign up

Quick links

Solutions

Contact